Emmerich J, Alhenc-Gelas M, Aiach M, Fiessinger J N
Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires Périphériques, Hôpital Broussais, Paris, France.
Biomed Pharmacother. 1996;50(6-7):254-60. doi: 10.1016/0753-3322(96)84822-0.
Activated protein C resistance is the most prevalent cause of thrombophilia: it is found in 20 to 30% of patients with a deep venous thrombosis history. Activated protein C resistance is due to an arginine 506 to glutamine mutation in factor V. This mutation prevents normal inactivation of activated factor V by activated protein C. The estimated increase in relative risk of venous thrombosis is 5- to 10-fold in heterozygotes, and 50- to 100-fold in homozygotes. Activated protein C resistance does not seem to play a role in arterial thrombosis and in the occurrence of myocardial infarction.
活化蛋白C抵抗是血栓形成倾向最常见的原因:在有深静脉血栓形成病史的患者中,20%至30%可检测到该情况。活化蛋白C抵抗是由于凝血因子V中精氨酸506突变为谷氨酰胺所致。这种突变可阻止活化蛋白C正常灭活活化的凝血因子V。杂合子静脉血栓形成的相对风险估计增加5至10倍,纯合子则增加50至100倍。活化蛋白C抵抗似乎在动脉血栓形成和心肌梗死的发生中不起作用。